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INTRODUCTION
Bone tissue engineering has been an increasing field of research during the last years. The ideal approach for a regenerative application would consist in the use of cells from the patient, scaffolding materials and
differentiation growth factors. Bone morphogenetic protein-2 (BMP-2) is one such growth factors with a strong ability to induce new bone and cartilage formation and has been used as a powerful osteoinductive 
component of several late-stage tissue engineering products for bone grafting. In this work, we aimed at obtaining high yields of human recombinant BMP-2 in a stable, pure and biologically active form by use of a 
new bacteria expression system that circumvents the disadvantages of conventional recombinant protein preparation methods and to perform a study of the stability conditions and functionality of these peptides in 
vitro in human mesenchymal stem cells and C2C12 murine cell line.  
CONCLUSIONS
Ø The novel approach described herein shows to be a promising way for obtaining significant amounts of 
partially purified rhBMP-2 for use in future bone tissue engineering applications. 
RESULTS & DISCUSSION
Biological activity assays in mesenchymal stem cells
Fig. 4. A) Silver stained reduced SDS-PAGE reveals 
purification growth factor to up 95%. B) Non-reduced
western-blot permitted observe monomer, dimer and 
polymer fractions. 
Production and purification of rhBMP-2
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Fig. 9. Addition of 5-500ng/ml rhBMP-2 to human adipose 
mesenchymal stem cells resulted in changes of 
morphology. 10 days of cell culture.
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Fig. 11. MTS bioassay revealed no significant 
cytotoxicity of purified rhBMP-2 at 5-500ng/ml.  3, 7 
and 14 days of cell culture.
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Fig. 8. ALP bioassay revealed an increase in ALP levels 
with continuous  purified 5-500ng/ml rhBMP-2 
stimulation. 3, 7 and 14 days of cell culture.
Fig. 7. RT-PCR shows increase in markers of osteogenic differentiation such as Runx2/Cbfa1, Smad-5 and Osteocalcin
after 5 days of cell culture with our BMP-2. A) control, B) 500ng/ml, C) 1000ng/ml, D) 2000ng/ml, E) 5000ng/ml, F) 
500ng/ml commercial BMP-2, G) 1000ng/ml commercial BMP-2
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Fig. 10. von Kossa bioassay revealed evidence of 
bone nodule formation in bone marrow MSCs after 
stimulation with 500ng/ml purified rhBMP-2.
14 days of cell culture. 
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Morphology of C2C12
Fig. 5.  Effect of rhBMP-2 added to C2C12 after 5 days of cell 
culture. Changes in morphology are observed but not similar to 
positive control.
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MATERIALS & METHODS
Fig. 1. The sequence coding for mature rhBMP-2 was cloned in a pET-25b vector containing a periplasmatic 
secretion signal and a histidine tag for affinity chromatography purification.
Fig. 2. Expression of recombinant bacteria was performed in a 
fermentor allowing large yields of rhBMP-2, around 110mg/L.
rhBMP-2 was cloned in pET-25b vector, expressed in fermentor under controlled conditions in 
BL21DE3  E. coli strain, purified by affinity chromatography and size exclusion chromatography 
and tested in mesenchymal stem cells and C2C12 cell line. 
Fig. 3. pET-25b/BMP-2 vector
This novel approach allows secretion of soluble 
protein into periplasmatic space of E. coli
permitting in loco dimer formation.
Biological activity assays in C2C12
Fig. 6.  BMP-2 human signalling pathway which 
triggers differentiation of MSCs into osteoblasts.
- Osteocalcin
Runx2/Cbfa1
Dlx5
Smad pathway
- ALP
BMP-2 dimer
- Osterix
BMP receptor type I/II
P
P
A
B C
D E
F
G
Periplasmatic
leader
HSV tagBMP- 2 mature 
chain
6x His
tag
